Form 4: Director John Johnson Executes Stock Transactions at XERS

Director John Johnson of Xeris Biopharma Holdings, Inc. reported a sale of 15,000 shares and an acquisition of 24,193 restricted stock units and 32,996 stock options.

Summary

• Director John Johnson sold 15,000 shares of common stock at a weighted average price of $6.0948 per share.
• The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on August 13, 2025.
• The director acquired 24,193 restricted stock units (RSUs) which vest on June 4, 2026, or the next annual meeting date.
• The director was granted 32,996 stock options with an exercise price of $6.15, expiring on June 4, 2036.
• Following these transactions, the director's direct beneficial ownership stands at 707,276 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction represents standard director compensation and pre-planned liquidity rather than a change in company outlook.

Positives

• The director maintains a significant equity stake of 707,276 shares in the company.
• The sale was conducted via a pre-planned Rule 10b5-1 program, indicating a systematic approach rather than reactive selling.

Negatives

• The director reduced their direct holdings by 15,000 shares.

Risks

• Future share price volatility may impact the value of the newly granted stock options and RSUs.
• Vesting of equity awards is contingent upon continued service to the company.

Future Outlook

The filing does not provide forward-looking business guidance, focusing instead on director equity compensation and ownership changes.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the range upon request.

Industry Context

StockSavvy.ai notes that routine equity grants and pre-planned 10b5-1 sales are standard corporate governance practices for directors in the biopharmaceutical sector, reflecting typical compensation structures rather than shifts in company strategy.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard industry practice to mitigate concerns regarding insider trading.
• Equity-based compensation for directors is consistent with peer biopharma companies of similar market capitalization.

Corporate Governance

Stakeholder Impact

• Shareholders may view the pre-planned sale as neutral, while the equity grants serve to retain director service.

Next Steps

• Vesting of RSUs and stock options on June 4, 2026, or the date of the next annual meeting.

Key Dates

Keywords

Xeris Biopharma, XERS, Insider Trading, Form 4, Director Stock Sale, Equity Compensation